Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma

Investigational New Drugs

Volumn 26, Issue 4, 2008, Pages 387-392

  Park, Byeong Bae ^a   Im, Young Hyuck ^b   Hwang, In Gyu ^b   Lee, Sang Cheol ^b   Ahn, Jin Seok ^b   Ahn, Myung Ju ^b   Lim, Ho Yeong ^b   Kang, Won Ki ^b   Park, Keunchil ^b  

^a Hanyang University   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Cisplatin; Esophageal cancer; Ifosfamide; Mitomycin C; Salvage chemotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; IFOSFAMIDE; MITOMYCIN C;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 45849138954     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9126-3     Document Type: Article

References (21)

1. Enzinger PC, Ilson DH, Kelsen DP (1999) Chemotherapy in esophageal cancer. Semin Oncol 26:12-20
2. Kelsen DP, Ilson DH (1995) Chemotherapy and combined-modality therapy for esophageal cancer. Chest 107:224S-232S
3. Kies MS, Rosen ST, Tsang TK, Shetty R, Schneider PA, Wallemark CB, Shields TW (1987) Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer. Cancer 60:2156-2160
4. Hilgenberg AD, Carey RW, Wilkins EW Jr, Choi NC, Mathisen DJ, Grillo HC (1988) Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg 45:357-363
5. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M et al (1992) Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172-176
6. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, Imamura M, Shinoda M, Ikeuchi S, Kabuto T, Yamana H, Fukuda H (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31:419-423
7. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241-2252
8. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17:3188-3194
9. Allen SM, Duffy JP, Walker SJ, Darnton SJ, Cullen MH, Matthews HR (1994) A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 6:91-95
10. Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR (2003) Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol 21:4009-4015
11. Conroy T, Etienne PL, Adenis A, Wagener DJ, Paillot B, Francois E, Bedenne L, Jacob JH, Seitz JF, Bleiberg H, Van Pottelsberghe C, Van Glabbeke M, Delgado FM, Merle S, Wils J (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol 14:164-170
12. Heath EI, Urba S, Marshall J, Piantadosi S, Forastiere AA (2002) Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs 20:95-99
13. Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C (2003) Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 89:630-633
14. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15:955-959
15. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR (2004) Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 15:64-69
16. Montesano R, Hainaut P (1998) Molecular precursor lesions in oesophageal cancer. Cancer Surv 32:53-68
17. Scheithauer W (2004) Esophageal cancer: chemotherapy as palliative therapy. Ann Oncol 15(Suppl 4):iv97-iv100
18. Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F (2005) Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 92:2129-2133
19. Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL (2004) Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs 22:91-97
20. Millar J, Scullin P, Morrison A, McClory B, Wall L, Cameron D, Philips H, Price A, Dunlop D, Eatock M (2005) Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer 93:1112-1116
21. Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP (2005) A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology 69:130-134